🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to Jan Mumford, our well-deserved recipient of the 2024 John Zalcberg AO Award for Excellence in AGITG Research #AGITG24

This #WorldPancreaticCancerDay, @PanKind_APCF is funding two new projects at Garvan. Both projects aim to overcome one of the biggest challenges in treating pancreatic cancer: finding ways to help promising new treatments reach and fight cancer cells more effectively.

VIDEO | #Amplia CEO & MD Dr Chris Burns and COO Dr Rhiannon Jones discuss the significance of Amplia’s latest clinical data from the ACCENT trial, and what investors can expect from Amplia in 2025. Take a look: youtu.be/as23w84i1cs $ATX #clinicaltrial #pancreaticcancer #pharma

A $3.75 million grant from the Institute is supporting an innovative ‘personalised medicine framework’ that is giving hope to people with pancreatic cancer. Learn more about its progress: brnw.ch/21wPnHP

I'm very pleased to share that I have received a NHMRC Ideas grant to explore targeting fibrosis in combination with chemotherapy to improve treatment efficacy in pancreatic cancer. Also a big thank you to the CI/AI team - cant wait to get started! Invasion and Metastasis Lab Garvan Institute of Medical Research

Congratulations to CCB’s Philip Gregory, Quenten Schwarz and Michael Samuel, who have been awarded @NHMRC Ideas Grant funding for 2025. Well done!

Congratulations to Dr Brooke Pereira on receiving a Fulbright Future Scholarship. Her work in pancreatic cancer research Garvan will benefit from this international opportunity. #FulbrightScholar #CancerResearch

1/Delighted to announce the newest paper from our lab, “Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage”, is out today in Nature Cell Biology, nature.com/articles/s4155….

Today - on #WorldCancerDay - we're grateful to our research collaborators, whose expertise and dedication make our clinical trials possible. Equal gratitude goes to the trial participants, and their families, who share our hope of improving outcomes for patients. #ATX #Amplia

Want to join our lab and contribute to world-class cancer research in Sydney? We are looking for a new research assistant! 🔬🧫 Apply here: seek.com.au/job/81805571?t…

📢 Hunter Meeting 2025 - Abstract submissions close on Friday 14th February 2025, 5pm AEST! The Hunter Meeting promises a fabulous line-up of international and national speakers in 2025. Submit your abstract and register to attend! Link: huntermeeting.org.au/abstract-submi…

Check out our latest work on 7NEWS Sydney 🎥 Here, we report on targeting the NPY/NPY1R signalling axis to lessen #PancreaticCancer metastasis🔬👩🏼‍🔬 Garvan Institute of Medical Research Check it out here: youtu.be/TfBmrQ71Rq4?si…

$ATX | #Amplia has today announced that trial initiation activities for the planned pancreatic cancer trial in the US have begun. Read the ASX release: bit.ly/ATX-US-Trial #pancreaticcancer #clinicaltrial #drugdiscovery #innovation #cancertreatment

Integrins provide a bridge between cancer cells and the #ECM, playing a role in every stage of disease progression. 🌉 Drs. James Conway & Johanna Ivaska reveal the importance of integrin phosphorylation for cancer cell invasion. Nature Cell Biology 🔗 go.nature.com/3Sm35ex

$ATX UPDATE | #Amplia has today announced that a patient from ACCENT clinical trial in advanced #pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the #ASX release: bit.ly/ATX_pCR

#Amplia has made headlines today following the announcement of a “pathological complete response” in an advanced #pancreaticcancer patient today. Biotech journalist Tim Boreham noted that Amplia shares had soared almost 50% following the news. Take a look: bit.ly/ATX-Stockhead_…

Did you catch this summary of the latest results from Amplia's ACCENT clinical trial in Small Caps this week? Take a look: bit.ly/ATX-SmallCaps-… $ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #innovation

We’re excited to share news from the Amplia Therapeutics ACCENT trial: one patient with advanced pancreatic cancer showed no remaining cancer cells after treatment. This complete response is extremely rare in this aggressive cancer type.

$ATX | #Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release: bit.ly/ATX_SecondCR #pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX